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AbstrAct
Introduction Human papillomavirus (HPV), a sexually 
transmitted infection, can cause anogenital warts and a 
number of cancers. To prevent morbidity and mortality, 
three vaccines have been licensed and are recommended 
by Canada’s National Advisory Committee on Immunisation 
(for girls since 2007 and boys since 2012). Nevertheless, 
HPV vaccine coverage in Canada remains suboptimal in 
many regions. This study will be the first to concurrently 
examine the correlates of HPV vaccine decision-making 
in parents of school-aged girls and boys and evaluate 
changes in parental knowledge, attitudes and behaviours 
over time.
Methods and analysis Using a national, online survey 
utilising theoretically driven constructs and validated 
measures, this study will identify HPV vaccine coverage 
rates and correlates of vaccine decision-making in 
Canada at two time points (August–September 2016 
and June–July 2017). 4606 participants will be recruited 
to participate in an online survey through a market 
research and polling firm using email invitations. Data 
cleaning methods will identify inattentive or unmotivated 
participants.
Ethics and dissemination The study received research 
ethics board approval from the Research Review Office, 
Integrated Health and Social Services University Network 
for West-Central Montreal (CODIM-FLP-16–219). The 
study will adopt a multimodal approach to disseminate 
the study’s findings to researchers, clinicians, cancer and 
immunisation organisations and the public in Canada and 
internationally.
IntroductIon
Human papillomavirus (HPV) is the most 
common sexually transmitted infection.1–4 
While most HPV infections are asymptom-
atic and do not progress to disease,5–7 some 
infections can cause substantial morbidity 
and mortality.8–11 It is estimated that 5.2% 
of all worldwide cancers are attributable to 
HPV.11–13 HPV-associated cancers include 
cervical, oropharyngeal, anal, vaginal, vulvar 
and penile.9 11 Combined, HPV is responsible 
for over 4000 new cancer cases annually in 
Canada.9 Certain strains of HPV (eg, HPV 
6/11) also cause anogenital warts.14 HPV-as-
sociated disease can impact quality of life 
and accrue substantial costs to the healthcare 
system.9 10 15 
Three prophylactic vaccines that prevent 
against the oncogenic strains of HPV have 
been developed and recommended: the 
bivalent Cervarix, quadrivalent Gardasil and 
nonavalent Gardasil.9 16 These vaccines are 
safe and effective.17–23 Canada’s National 
Advisory Committee on Immunisation 
(NACI) has recommended the HPV vaccines 
for girls (since 2007) and boys (since 2012) 
ages 9–26.2 16 From 2007 to 2010, all Cana-
dian provinces and territories implemented 
publicly funded, school-based vaccination 
programmes for girls, although at different 
ages (ie, 9–13 years of age) and with different 
dosing schedules (ie, two or three doses).24 25 
Vaccinating children at this age provides the 
highest level of immunogenicity and protects 
individuals before they are sexually active and 
thereby at risk of infection.9 20 This approach 
is similar to the majority of countries that 
provide publicly funded HPV vaccination 
programmes to girls.26
To date, only a handful of countries have 
extended their publicly funded, school-based 
HPV vaccination programmes to boys.25 27 28 
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Protocol
strengths and limitations of this study
 ► Strengths of the study include a large sample size 
(n=4606), a nationally representative sample, use 
of psychometrically validated scales, the use of 
theoretical frameworks, a mixed methods approach, 
a wider range of constructs than in previous studies 
and sophisticated data cleaning techniques to 
exclude inattentive or unmotivated responders.
 ► Limitations of this study include relying on self-
reported data.
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Figure 1 Publicly funded school-based HPV vaccine programmes in Canada. This figure identifies the year that publicly 
funded school-based HPV vaccine programmes were initiated for girls and boys by Canadian jurisdiction.
Canada has been an international leader in providing 
gender-neutral HPV vaccination;25 by September 2017, 
10 of Canada’s 13 regions will have commenced school-
based HPV vaccination programmes that include boys 
(figure 1).29–36 However, implementation of male HPV 
vaccination across Canada has been staggered, presenting 
a natural experiment to evaluate and compare the impact 
of the introduction of the HPV vaccine programmes on 
parents’ attitudes, knowledge and vaccine coverage.
Achieving high levels of vaccine coverage protects indi-
viduals and helps prevent transmission to unvaccinated 
partners, which maximises population-level effective-
ness (ie, through herd protection).37 HPV vaccination 
programmes in Canada are not reaching their target 
rates of immunisation.38 39 HPV vaccine uptake rates in 
Canada vary considerably by region; in a national survey 
of parents of girls aged 12–14 years, Gilbert et al reported 
vaccination rates between 52.6% and 89.7% (2013 data).40 
On average, HPV vaccine uptake across Canada was 
72.3%.40 Preliminary evidence for boys in PEI’s school-
based vaccination programme indicates 85.4% vaccine 
uptake (2013/2014 data).29 However, a national survey 
of Canadian parents found uptake rates for boys in the 
context of (only one then two) publicly funded school-
based programmes was extremely low (<3% nationwide; 
2013 data).41 The lack of a national immunisation registry 
makes it difficult to compare HPV vaccine coverage rates, 
and no national survey has yet examined HPV vaccine 
coverage in girls and boys simultaneously.
Given that parental consent is required for school-
based immunisation programmes for children in Canada, 
the NACI and Canadian Immunisation Committee (CIC) 
have made it a research priority to understand why 
parents delay or refuse to vaccinate their children.9 24 
Accordingly, this study seeks to understand the sociode-
mographic, psychosocial and behavioural correlates of 
HPV vaccine coverage. Over the last decade, a number of 
studies have identified factors associated with HPV vacci-
nation decision-making including demographics, knowl-
edge, attitudes, social norms, logistics (eg, time, effort) 
and cost.42–53 The evidence has indicated some common 
themes (eg, the importance of physician recommenda-
tion, perceived benefit, perceived safety, cost), and some 
contradictory evidence (eg, knowledge has been found 
to correlate both negatively and positively with vaccine 
acceptance).48 49 54 The degree to which each of these 
factors contributes (ie, the effect size) and possible policy 
variations between jurisdictions remains largely unclear. 
In addition, despite several systematic reviews,48 49 51 53 55 
not all potentially relevant factors (eg, the effect of vaccine 
conspiracy beliefs) have been identified or comprehen-
sively investigated in large population-based studies, 
especially in the Canadian context.56 Furthermore, the 
majority of studies addressing parental HPV vaccine 
decision-making have been primarily focused on parents 
of girls,40 57 with fewer studies evaluating and making 
comparisons with parental HPV vaccine decision-making 
for boys.58–60
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The present study aims to address these research 
gaps. Using a national, online survey utilising theoreti-
cally driven constructs and validated questionnaires, this 
study identifies HPV vaccine coverage and correlates of 
decision-making in Canada. It will be the first to study 
concurrently the correlates of decision-making in Cana-
dian parents of eligible school-aged girls and boys. This 
study will administer a survey at two time points (August–
September, 2016 and June–July, 2017) to capture 
important factors related to HPV vaccine hesitancy, accep-
tance and variation over time. Accordingly, this study will 
elucidate psychosocial factors that influence parents to 
vaccinate their daughters or sons contemporaneously 
and evaluate changes in parental knowledge, attitudes 
and behaviours over time.
study objectives and hypotheses
The main objectives of this study are as follows:
1. To describe HPV vaccine coverage in Canadian girls 
and boys
In the absence of a national immunisation registry,61 
current information on HPV vaccine coverage is un-
clear and continually evolving. We aim to determine 
HPV vaccine coverage in girls and boys nationally and 
across Canadian jurisdiction, and how rates change 
over time.
2. To assess the correlates of HPV vaccination in parents 
of girls and boys
In order to improve programmes, it is important to 
understand the factors associated with HPV vaccine 
uptake. To date, Canadian studies have assessed the 
correlates of HPV vaccine uptake in parents of girls 
and parents of boys separately.52 58 Because the HPV 
vaccine is available to girls and boys of varying ages, 
we aim to understand the determinants of HPV vac-
cine uptake in these groups, using constructs from 
the Health Belief Model (HBM), a commonly used 
theoretical model that includes core beliefs that are 
hypothesised to predict the adoption of new health 
behaviours.62 The HBM has been used to examine 
various health-related behaviours, including cancer 
prevention and vaccination.63 64 As applied to HPV 
vaccination, elements of the HBM include perceived 
benefits of, and barriers to, HPV vaccination; per-
ceived severity of, and susceptibility to, HPV infection 
and disease and external influences prompting HPV 
vaccine uptake (ie, cues to action). This study will use 
HBM constructs and other important predictors to 
evaluate, compare and contrast. We hypothesise that 
higher HPV vaccine uptake will be significantly relat-
ed to greater HPV knowledge, HBM constructs (par-
ticularly lower ‘barriers’ and more ‘cues to action’), 
non-HBM attitudinal constructs (eg, lower vaccine 
conspiracy beliefs) and healthcare provider (HCP) 
recommendation. In parents of boys, a publicly fund-
ed programme (that reduces barriers of cost and ac-
cess) and HCP recommendation are hypothesised to 
be particularly important.
3. To identify Canadian parents’ stage of decision-mak-
ing by gender and province
Few studies have examined the stages of parents’ vac-
cine decision. Assessing differences in parents’ HPV 
vaccine decision-making stage is important for iden-
tifying how best to intervene for parents at different 
stages.58 65 Using the Precaution Adoption Process 
Model (PAPM), a stage-based theoretical model, we 
will classify parents according to their unique stage of 
HPV vaccine decision-making and examine the asso-
ciated attitudes with that stage.65–67 The PAPM, as ap-
plied to HPV vaccination, identifies individuals along 
six stages of decision-making: (1) unaware of the vac-
cine, (2) unengaged in the decision to vaccinate their 
child, (3) undecided about whether to vaccinate their 
child, (4) decided not to act (ie, decided not to vaccinate 
their child), (5) decided to act (ie, decided to vaccinate 
their child) and (6) acted (ie, vaccinated their child) 
(see online supplementary material 1). We will com-
pare the stage of decision-making of parents of girls 
with boys, as well as the stages of parents in those re-
gions that have publicly funded programmes for boys 
at Time 1 (ie, Alberta, Nova Scotia, PEI) with those 
that do not (ie, British Columbia, Manitoba, New 
Brunswick, Newfoundland and Labrador, Northwest 
Territories, Nunavut, Ontario, Saskatchewan, Que-
bec, Yukon). We hypothesise that parents of boys will 
be in earlier PAPM stages compared with parents 
of girls and that parents of boys in regions without 
an HPV vaccine programme will be in earlier stages 
compared with parents of boys in regions with a pro-
gramme.
4. To determine the impact of publicly funded HPV 
vaccine programme initiation for boys
HPV vaccination programmes for boys were imple-
mented in Quebec, Ontario and Manitoba in the Fall 
of 2016, which is after Time 1 survey administration 
(August–September 2016), but before launching the 
Time 2 survey (June–July 2017). This natural experi-
ment allows us to evaluate the impact of introducing a 
public school-based HPV vaccination programme on 
parents’ HPV vaccine knowledge, attitudes and HPV 
vaccine coverage. Accordingly, we will assess whether 
these factors change from Time 1 to Time 2. We hy-
pothesise that compared with programmes with no 
change to their public vaccination programme, at 
Time 2 (post-intervention) parents of boys in Manito-
ba, Ontario and Quebec will have increased HPV vac-
cine knowledge, more positive HPV vaccine attitudes, 
be more likely to have received a HCP’s recommenda-
tion and be more likely to have received the HPV vac-
cine. British Columbia, Saskatchewan, New Brunswick 
and Newfoundland and Labrador have announced 
that they would fund HPV vaccine for boys to begin 
in September 2017 (figure 1); this research will there-
fore have value in predicting how parental attitudes 
regarding vaccinating their sons might change in 
those jurisdictions.




This study uses a longitudinal design to collect self-re-
ported data through an online questionnaire from a 
large national sample of Canadian parents. Surveys are 
administered at two time points: Time 1 during August–
September (2016) and Time 2 during June–July (2017). 
Participants who responded to the survey at Time 1 were 
contacted again at Time 2 using the same questionnaire.
sample
This study targets parents and guardians (hereafter 
referred to as ‘parents’) of 9 to 16 year old girls and 
boys  across Canada. This population is targeted because, 
on the younger side (ie, age 9), it includes the youngest 
children included in NACI’s recommendation and, on the 
older side (ie, age 16), it includes children who, generally 
speaking, require parental consent in Canada.68 Parents 
will be recruited by Canada’s largest market research and 
polling firm, Leger—The Research Intelligence Group. Leger 
maintains a national panel of 400 000 Canadians who 
have internet access, reside in Canada and are fluent in 
English or French. This study targeted parents who have 
a child between 9 and16 years of age living in their house-
hold. Participants completing the questionnaire at Time 
1 will be contacted again at Time 2.
Leger’s panels include individuals of all profiles with 
regard to gender, age, education level, household compo-
sition and income for all regions, making it feasible to 
target specific participants effectively.67 The panel is 
constructed to be nationally, as well as regionally, repre-
sentative. Leger uses proprietary software informed by 
Canada’s census data in order to generate a representa-
tive sample of the population. Leger’s software follows 
an interactive algorithm to invite participants according 
to specified eligibility criteria. In this study, Leger’s soft-
ware enables extraction of all active and available panel-
lists who meet the screening criteria, random sorting of 
the selected sample pool, examination of the number 
of panellists who satisfy each target group (ie, parents of 
girls aged 9–16 year or parents of boys aged 9–16 year) 
and recalculation and balancing of the sample across 
the target groups. To recruit participants, Leger sends 
an email invitation and survey link to selected panel-
lists. Leger sends a maximum of three reminder emails 
to its selected panellists to complete the survey until the 
required numbers of participants are recruited.
This study’s sample size calculation takes into account 
previous research indicating that approximately 15% of 
respondents are inattentive or unmotivated responders 
who would be excluded when using rigorous data 
cleaning methods.66 69 To evaluate different stages of 
decision-making (objective 3), we are guided by previous 
research that found few individuals in particular stages 
(especially in less populated regions).66 An attrition rate 
(of approximately 40%–50%) from the first wave of data 
collection (Time 1, August–September 2016) to the 
second wave (Time 2, June–July 2017) is also expected.66 
Therefore, in order to attain a sufficient number of respon-
dents to enable analyses of HPV vaccine decision-making 
by stage and region, this study recruits approximately 
4600 parents of school-aged children (ages 9–16) at Time 
1, equally divided between parents of girls and parents of 
boys.
Measures
We use an online questionnaire that incorporates intel-
ligent programming, such that the child’s first name is 
included in the survey questions and parents receive 
questions that are personalised for them. Questionnaire 
items include previously validated scales.70–74 Partici-
pants will be asked to identify themselves as a parent or 
guardian, report the number of children they have and 
their children’s ages and genders. Parents with more than 
one child who meet the inclusion criteria will be asked 
to answer the questionnaire for the child who has had 
the most recent birthday, a randomisation technique 
previously employed.66 The questionnaire assesses socio-
demographics, HPV and HPV vaccine knowledge (using 
validated scales),71 PAPM stage, HPV vaccine willingness, 
HPV vaccine coverage, HCP recommendation (including 
the strength of the recommendation), HPV attitudes 
(using validated scales),73 75 motivation towards vaccina-
tion, vaccine hesitancy (using a developed scale)74 and 
vaccine conspiracy beliefs (using a validated scale).70 
Items within validated questionnaires are administered 
in a random order to ameliorate any order effect and 
invariant responding.76 Five open-ended qualitative ques-
tions will provide nuance in capturing details of parents’ 
subjective perspectives on decision-making.77 A detailed 
description of the questionnaire’s items can be found in 
the online supplementary material 1.
To take into account language and literacy level, the 
questionnaire was adjusted to a grade eight reading level. 
To ensure the questionnaire could be answered in either 
of Canada’s national languages, the English questionnaire 
was translated into French using Asiatis, an international 
translation service company. Bilingual team members 
verified the French translation and back translation.
data collection and management
Leger will facilitate data collection. Participants will be 
sent an email invitation to participate in a questionnaire 
and then assigned a unique access number. By accessing 
the questionnaire with this unique number, the respon-
dent enters a secure account that ensures confidentiality. 
Moreover, if necessary, respondents may stop and resume 
the questionnaire where they left off so that they partic-
ipate at a time that best suits them, allowing them to 
complete the questionnaire conscientiously.
Participants will be paid a modest cash amount in 
accordance with standard panel member compensa-
tion of Leger. Data collection at both time periods will 
be completed within four weeks. Missing data will not 
be an obstacle in this survey because participants will be 
required to answer all questions before moving from one 
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page to the next. Once participants complete the ques-
tionnaire, they will be debriefed, informed about HPV 
vaccination and provided with informational resources. 
Leger will transfer the anonymised raw data file to our 
research team, which will be stored on a secure server at 
the Lady Davis Institute for Medical Research site of the 
Integrated Health and Social Services University Network 
for West-Central Montreal.
data cleaning procedure
As recommended in the literature,69 76 78 data cleaning 
methods will be used to identify participants who might 
not have used appropriate care while completing the ques-
tionnaire (ie, inattentive or unmotivated responders). 
Consistent with DeSimone et al (2015) and Perez et 
al (2016), we will use data cleaning methods that are 
direct (ie, bogus items) and statistical (ie, psychometric 
synonyms and psychometric antonyms).66 76
Bogus items will be used to screen inattentive or unmo-
tivated responders. Two bogus items on Likert scales 
were randomly inserted into the survey: ‘I have never 
met anyone younger than I am’ and ‘I have been to 
every country in the world’ (measured from ‘1—strongly 
disagree’ to ‘7—strongly agree’). Incorrect answers (ie, 
agreement) to both bogus items suggest inattentive or 
unmotivated responders. Incorrect responses are indica-
tive of lack of attention. Respondents who answer at least 
one bogus item correctly will be retained.
Psychometric synonyms and antonyms data cleaning 
methods statistically examine response patterns.66 
Providing different responses to similar items suggests 
insufficient attention and accuracy in answering the 
questionnaire. Items measured on Likert scales will be 
selected and inter-item correlations will be calculated. 
Positively correlated pairs of items will constitute psycho-
metric synonyms while negatively correlated pairs will 
constitute psychometric antonyms.76 The number of 
pairs cannot be anticipated before beginning data anal-
ysis because it depends on the degree of correlation and 
the chosen cut-off value of the correlation coefficient.76 
We will use an inter-item Pearson correlation cut-off of 
0.60 and −0.60 for selecting psychometric synonyms and 
psychometric antonyms pairs, respectively, consistent with 
recommendations of Meade and Craig (2012).78 Once 
the pairs have been identified, an index will be calculated 
for each respondent by correlating the responses to the 
first items of the pairs with the responses to the second 
items of the pairs.
Responders who meet both the bogus item and the 
psychometric synonyms/antonyms criteria will be consid-
ered attentive responders and retained.
data analysis plan
In line with the first research objective to provide an accu-
rate description of HPV vaccine coverage, we will report 
HPV vaccination coverage as percentage of girls and boys 
in each region and age group whose parents report they 
have received one, two or three doses of the HPV vaccine. 
To test for statistically significant differences in propor-
tions, we will use Pearson’s Χ2 square tests and two sample 
tests of proportions.
For the second objective, to assess the correlates of HPV 
vaccine uptake in Canada, HPV vaccine uptake (depen-
dent variable) will be dichotomised into ‘vaccinated’ 
(ie, received at least one dose of the HPV vaccine) and 
‘non-vaccinated’. Logistic regressions will be used to esti-
mate the odds of vaccine uptake based on the correlates 
of interest, including sociodemographics, attitudes 
(informed by the HBM), knowledge and behaviours (eg, 
discussion with HCP). Significant associations between 
the correlates and vaccine uptake will be tested using 
bivariate logistic regression analyses. Multivariate logistic 
regression modelling will then be performed with all 
correlates from the bivariate analysis entered simulta-
neously. The model will be tested for goodness of fit, 
discrimination capacity and multicollinearity.
To identify Canadian parents’ stage of decision-making 
by gender and region (objective 3), we will report 
parents’ HPV vaccine decision-making in percentages 
based on the six stages of the PAPM. For assessing signif-
icant differences in PAPM stage based on gender (at 
Time 1) and availability of publicly funded HPV vaccina-
tion programmes for boys (at both Time 1 and Time 2), 
Pearson Χ2 test and two sample tests of proportions will 
be used.
Lastly, to determine the impact of publicly funded HPV 
vaccine programme initiation for boys in some regions, 
we will examine changes in parents’ of boys (HPV and 
HPV vaccine) knowledge and attitudes (eg, on the HPV 
Attitudes and Beliefs Scale, Vaccine Conspiracy Beliefs 
Scale and Vaccine Hesitancy Scale) before and after 
the introduction of the funded programme. Parents of 
boys in provinces that introduced the programme will be 
compared with parents of boys in regions with no change 
to their programme. Significant differences from Time 1 
to Time 2 will be tested using paired t-tests.
EthIcs And dIssEMInAtIon
study ethics
The study received research ethics board approval from 
the Research Review Office, Integrated Health and Social 
Services University Network for West-Central Montreal 
(CODIM-FLP-16–219). This is a university-affiliated 
teaching healthcare network where the coordinating 
centre (Lady Davis Institute for Medical Research) is 
based. Study participants consented to Leger’s terms of 
use and privacy policy, which indicates that their data will 
be used anonymously for the research study.
dissemination plan
The study will adopt a multimodal approach to dissemi-
nate the study’s results to researchers, clinicians, cancer 
and vaccination organisations and the public in Canada 
and internationally. Study findings will be published 
in peer-reviewed scientific journals (including open 
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source). To assure wide availability of our results to the 
research community, journals will be selected that reach 
both research and health professional audiences.
Presentations will be made at national and interna-
tional scientific meetings and symposia, such as the Cana-
dian Immunisation Conference, Canadian Association 
of Psychosocial Oncology, International Papillomavirus 
Conference and the International Psycho-Oncology 
Society. In addition, we will share the results with NACI, 
CIC and provincial immunisation advisory boards.
Given that the data is timely and could have immediate, 
direct implications for public education of Canadian 
parents and more widespread influence on public health 
policy, we will prioritise analysis and dissemination of proj-
ects that have a potential for proximal public impact. We 
hope that sharing outcomes with non-profit organisations 
(eg, the Canadian Cancer Society) will provide important 
platforms for innovative educational interventions based 
on this study’s findings.
We will draft lay research summaries in media releases 
for dissemination to national media outlets to help the 
public understand the importance of this research. Media 
releases will also be used to bring the issues and challenges 
related to HPV vaccine acceptance to the public domain 
in order to inform discussions about HPV vaccination.
dIscussIon
study implications
By surveying a population-based representative sample of 
parents of eligible children, this study will provide current 
information about HPV vaccine coverage rates for both 
girls and boys nationally and across Canadian jurisdic-
tions (objective 1). Since HPV vaccine programmes and 
policies are constantly evolving,25 it is timely to evaluate 
comprehensively variations in programme outcomes that 
target girls and boys, jurisdictions at a national and local 
level and HPV vaccination by sociodemographic groups. 
For this reason, this study will be useful to policymakers in 
understanding where the HPV vaccination programmes 
are meeting coverage targets, where disparities in vaccina-
tion exist, and which groups or jurisdictions may benefit 
from interventions designed to increase vaccination.
In order to improve the impact of publicly funded 
HPV vaccination programmes, this study will examine 
the psychosocial and behavioural factors associated with 
parents’ decisions to vaccinate their children and their 
decision-making stage (objectives 2 and 3). These theo-
retically driven investigations will enable policymakers 
to develop interventions to increase HPV vaccination 
that are evidence-based, tailored and targeted towards 
parents’ unique informational needs and their stage of 
decision-making, rather than providing all parents with 
the same messages.
Lastly, since Canada is one of the few countries that have 
implemented publicly funded, national HPV vaccination 
programmes, this research will make use of a natural 
experiment to evaluate the impact of the introduction of 
funded programmes for boys on parents’ vaccine knowl-
edge, attitudes and decision to vaccinate (objective 4). 
The results of this study will improve our understanding 
of the complex interplay of psychosocial and behavioural 
factors with policy decisions. By understanding this 
complexity, other countries can better anticipate the 
impact of policy changes on vaccination.
The results generated by the study’s four objectives 
will provide public health officials with critical informa-
tion about HPV vaccination programmes, improve the 
field's understanding of influencers of decision-making, 
enhance the delivery of publicly funded HPV vaccina-
tion programmes, facilitate HPV vaccine uptake and in 
turn decrease Canada’s cancer burden and the associated 
human and economic cost.
Methodological strengths
The recruitment strategy of using a marketing company 
(Leger) that maintains a nationally representative panel 
for data collection enables the sampling of a large 
number of parents who answer the survey within a short 
time frame. The precise recruitment period allows for 
data collection to occur in a timely manner and the 
provision of a snapshot of responses before and after the 
implementation of the HPV vaccination programme for 
boys in certain provinces.
In addition, we use an online survey methodology with 
intelligent programming, which increases the quality of 
collected data by personalising and tailoring the survey 
for each participant. This study also avoids the problems 
associated with missing data. To avoid the limitation of 
inattentive or unmotivated responding that is often 
found in survey data, this study will utilise sophisticated 
data cleaning techniques to remove such responders.
Further, the measures used in this study include 
psychometrically validated scales (where possible), which 
increase the reliability and validity of our results. Our 
survey also assesses diverse constructs. By using theoret-
ical frameworks (such as the HBM and PAPM), we will 
be able to better understand the vaccine acceptability 
process, which is important in nuanced targeting of inter-
ventions. Lastly, by including quantitative and qualita-
tive (open-ended) questions, we will be able to conduct 
additional mixed-methods analyses to examine in-depth 
explanations of HPV vaccine decision-making at different 
stage levels.
Foreseeable limitations
One limitation of this study is the reliance on parents’ 
self-reports of vaccination status for their children. In 
order to minimise this limitation, parents are asked about 
their child's vaccination status before and after reading 
an informative statement (whereby parents are provided 
details about the HPV vaccine). The exact number of 
reported doses (two or three) could also be inaccurate. A 
possible way to confirm immunisation status is to request 
parents to check the immunisation record, contact the 
family doctor or link to provincial immunisation records. 
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However, requesting participants to access records is not 
feasible in our study as such a request would significantly 
increase the data collection time and costs. Another 
limitation of this study’s design is that because we assess 
the same population at two time points, this study does 
not control for knowledge changes that occur as a result 
of the first survey. As our study’s objective (objective 
4) is to compare provinces with and without provincial 
funding, this study makes the assumption that knowledge 
changes as a result of the first survey affects individuals 
from all provinces equally.
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